ArticleFrontiers in neurology2019

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of CX-8998, a Selective Modulator of the T-Type Calcium Channel in Inadequately Treated Moderate to Severe Essential Tremor: T-CALM Study Design and Methodology for Efficacy Endpoint and Digital Biomarker Selection.

Spyros Papapetropoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.